Skip to main content
. 2014 Dec 29;10(1):134–142. doi: 10.1097/JTO.0000000000000366

FIGURE 2.

FIGURE 2.

A, Kaplan-Meier plot of primary end point G4 progression-free survival, (B), Kaplan-Meier plot showing the progression-free survival in intent-to-treat population, (C), Kaplan-Meier plot showing the overall survival in intent-to-treat population. Bev, bevacizumab; Cb, carboplatin; G4PFS, grade 4 progression-free survival; HR, hazard ratio; OS, overall survival; Pac, paclitaxel; Pem, pemetrexed; PFS, progression-free survival.